



FORM PTO - 1449

ATTORNEY DOCKET NO.: LEX-003

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENTAPPLICANT(S): Gillies *et al.*

SERIAL NO.: 09/256,156

FILING DATE: February 24, 1999 GROUP: 1647

U.S. PATENT DOCUMENTS

| EXAM. INIT. | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE |
|----------------|------|--------------------|----------|------------------|-------|--------------|-------------------------------|
| RKH | A95 | 5,601,819 | 2/11/97 | Wong et al. | | | |
| | A96 | 5,624,821 | 4/29/97 | Winter et al. | | | |
| | A97 | 5,679,543 | 10/21/97 | Lawlis | | | |
| | A98 | 5,891,680 | 4/6/99 | Lieschke et al. | | | |
| | A99 | 5,994,104 | 11/30/99 | Anderson et al. | | | |
| | A100 | 6,429,199 | 8/6/02 | Krieg et al. | | | |
| | A101 | 6,551,592 | 4/22/03 | Lindhofer et al. | | | |
| | A102 | 6,646,113 | 11/11/03 | Dreyfuss et al. | | | |
| | A103 | 2002/0037558 | 3/28/02 | Lo et al. | | | |
| | A104 | 2002/0146388 | 10/10/02 | Gillies | | | |
| | A105 | 2003/0139365 | 7/24/03 | Lo et al. | | | |
| | A106 | 2003/0139575 | 7/24/03 | Gillies | | | |
| | A107 | 2004/0033210 | 2/19/04 | Gillies | | | |
| | A108 | 2004/0053366 | 3/18/04 | Lo et al. | | | |
| | A109 | 2004/0072299 | 4/15/04 | Gillies et al. | | | |
| RKH | A110 | 2004/0082039 | 4/29/04 | Gillies et al. | | | |

FOREIGN PATENT DOCUMENTS

| EXAM. INIT. | | DOCUMENT NUMBER | DATE | COUNTRY CODE | CLASS | SUB CLASS | FILING DATE | ABSTRACT ONLY | ENGLISH LANG (Y/N) |
|----------------|------|--------------------|----------|-----------------|-------|--------------|----------------|------------------|--------------------------|
| RKH | B106 | WO 93/20185 | 10/14/93 | PCT | | | | | |
| RKH | B107 | WO 97/43316 | 11/20/97 | PCT | | | | | |

EXAMINER

Ronald K. Hunsicker

DATE CONSIDERED

9/7/04



| | | | |
|--|--|--|------------------------|
| FORM PTO - 1449 | | ATTORNEY DOCKET NO.: LEX-003 | |
| SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT | | APPLICANT(S): Gillies <i>et al.</i> | |
| | | SERIAL NO.: 09/256,156 | |
| | | FILING DATE: February 24, 1999 GROUP: 1647 | |
| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | | |
| RKH | C236 | Batra et al., (1993), "Insertion of Constant Region Domains of Human IgG1 into CD4-PE40 Increases Its Plasma Half-Life," <u>Molecular Immunology</u> , 30(4):379-386. | |
| | C237 | Chapman et al., (1994), "Mapping Effector Functions of a Monoclonal Antibody to GD3 by Characterization of a Mouse-Human Chimeric Antibody," <u>Cancer Immuno. Immunother.</u> , 39:198-204. | |
| | C238 | Cruse et al., (eds.), (1995), <u>Illustrated Dictionary of Immunology</u> , p.158, CRC Press, NY. | |
| | C239 | de la Salle et al., (1996), "FcγR on Human Dendritic Cells," in <u>Human IgG Receptors</u> , pp. 39-55, van de Winkel et al. (eds.), R.G. Landes Co. | |
| | C240 | Dorai et al., (1991), "Aglycosylated Chimeric Mouse/Human IgG1 Antibody Retains Some Effector Function," <u>Hybridoma</u> , 10(2):211-217. | |
| | C241 | Dorai et al., (1992), "Role of Inter-Heavy and Light Chain Disulfide Bonds in the Effector Functions of Human IgG1," <u>Molecular Immunology</u> , 29(12):1487-1491. | |
| | C242 | Elliott et al., (1996), "Fine-Structure Epitope Mapping of Antierythropoietin Monoclonal Antibodies Reveals a Model of Recombinant Human Erythropoietin Structure," <u>Blood</u> , 87(7):2702-2713. | |
| | C243 | Gillies et al., (1991), "Targeting Human Cytotoxic T Lymphocytes to Kill Heterologous Epidermal Growth Factor Receptor-Bearing Tumor Cells: Tumor-Infiltrating Lymphocyte/Hormone Receptor/Recombinant Antibody," <u>J. Immunology</u> , 146(3):1067-1071. | |
| | C244 | Handgretinger et al., (1995), "A Phase I Study of Human/Mouse Chimeric Anti-ganglioside GD2 Antibody ch14.18 in Patients with Neuroblastoma," <u>European J. Cancer</u> , 31A(2):261-267. | |
| | C245 | Harvill et al., (1995), "An IgG3-IL2 Fusion Protein Activates Complement, Binds FcγRI, Generates LAK Activity and Shows Enhanced Binding to the High Affinity IL-2R," <u>Immunotechnology</u> , 1:95-105. | |
| | C246 | Harvill et al., (1996), "In Vivo Properties of an IgG3-IL-2 Fusion Protein: A General Strategy for Immune Potentiation," <u>J. Immunology</u> , 157(7):3165-3170. | |
| | C247 | Hurn et al., (1980), "Production of Reagent Antibodies," <u>Methods in Enzymology</u> , 70: 104-142. | |
| | C248 | Isenman et al., (1975), "The Structure and Function of Immunoglobulin Domains: II. The Importance of Interchain Disulfide Bonds and the Possible Role of Molecular Flexibility in the Interaction between Immunoglobulin G and Complement," <u>J. Immunology</u> , 114(6):1726-1729. | |
| | C249 | Lo et al., (1992), "Expression and Secretion of an Assembled Tetrameric CH2-deleted Antibody in <i>E. Coli.</i> ," <u>Hum. Antibod. Hybridomas</u> , 3:123-128. | |
| RKH | C250 | Maecker et al., (1997), "DNA Vaccination with Cytokine Fusion Constructs Biases the Immune Response to Ovalbumin," <u>Vaccine</u> , 15(15):1687-1696. | |
| EXAMINER | Rahul K. Himmeth | | DATE CONSIDERED 9/7/04 |



PTO - 1449

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-003

APPLICANT(S): Gillies *et al.*

SERIAL NO.: 09/256,156

FILING DATE: February 24, 1999 GROUP: 1647

EXAM.
INIT.

OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)

| | | |
|-----|------|--|
| RKH | C251 | Mueller et al., (1990), "Enhancement of Antibody-Dependent Cytotoxicity With A Chimeric Anti-GD2 Antibody," <u>J. Immunology</u> , 144(4):1382-1386 |
| | C252 | Mueller et al., (1990), "Serum Half-Life and Tumor Localization of a Chimeric Antibody Deleted of the CH2 Domain and Directed Against the Disialoganglioside GD2," <u>Proc. Natl. Acad. Sci. USA</u> , 87:5702-5705. |
| | C253 | Naramura et al., (1993), "Therapeutic Potential of Chimeric and Murine Anti-(Epidermal Growth Factor Receptor) Antibodies in a Metastasis Model for Human Melanoma," <u>Cancer Immuno. Immunother.</u> , 37:343-349. |
| | C254 | Reisfeld et al., (1994), "Potential of Genetically Engineered Anti-Ganglioside GD2 Antibodies for Cancer Immunotherapy," <u>Prog. Brain Res.</u> , 101:201-212 |
| | C255 | Saleh et al., (1992), "Phase I Trial of the Chimeric Anti-GD2 Monoclonal Antibody ch14.18 in Patients With Malignant Melanoma," <u>Hum. Antibod. Hybridomas</u> , 3:19-24. |
| | C256 | Sallusto et al., (1994), "Efficient Presentation of Soluble Antigen by Cultured Human Dendritic Cells Is Maintained by Granulocyte/Macrophage Colony-stimulating Factor Plus Interleukin 4 and Downregulated by Tumor Necrosis Factor α ," <u>J. Exp. Med.</u> , 179:1109-1118. |
| | C257 | Schlom (1991), "Monoclonal Antibodies: They're More and Less Than You Think," in <u>Molecular Foundations of Oncology</u> , pp. 95-133. |
| | C258 | Wen et al., (1994), "Erythropoietin Structure-Function Relationships: Identification of Functionally Important Domains," <u>J. Biological Chemistry</u> , 269(36):22839-22846. |
| RKH | C259 | Xu et al., (1994), "Residue at Position 331 in the IgG1 and IgG4 CH2 Domains Contributes to Their Differential Ability to Bind and Activate Complement," <u>J. Biol. Chem.</u> , 269(5):3469-3474. |

EXAMINER

David K. Himmelfarb

DATE CONSIDERED

9/7/04

FORM PTO - 1449


SECOND SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-003

APPLICANT(S): Gillies *et al.*

SERIAL NO.: 09/256,156


FILING DATE: February 24, 1999 GROUP: 1647



U.S. PATENT DOCUMENTS

| EXAM & TRADEMARK INIT. | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE |
|---------------------------|------------------|--------------------|----------|---------------------|--------|--------------|-------------------------------|
| RKH | A55 | 4,703,008 | 10/27/87 | Lin | | | |
| / | A56 | 5,019,368 | 5/28/91 | Epstein et al. | | | |
| / | A57 | 5,441,868 | 8/15/95 | Lin | | | |
| / | A58 | 5,457,038 | 10/10/95 | Trinchieri et al. | | | |
| / | A59 | 5,547,933 | 8/20/96 | Lin | | | |
| / | A60 | 5,618,698 | 4/8/97 | Lin | | | |
| / | A61 | 5,645,835 | 7/8/97 | Fell, Jr. et al. | | | |
| / | A62 | 5,688,679 | 11/18/97 | Powell | | | |
| / | A63 | 5,756,349 | 5/26/98 | Lin | | | |
| / | A64 | 5,807,715 | 9/15/98 | Morrison et al. | | | |
| / | A65 | 5,856,298 | 1/5/99 | Strickland | | | |
| / | A66 | 5,888,772 | 3/30/99 | Okasinski et al. | | | |
| / | A67 | 5,922,685 | 7/13/99 | Rakhmilevich et al. | | | |
| / | A68 | 5,955,422 | 9/21/99 | Lin | | | |
| / | A69 | 6,231,536 | 5/15/01 | Lentz | | | |
| / | A70 | 6,284,536 | 9/4/01 | Morrison et al. | | | |
| / | A71 | 6,335,176 | 1/1/02 | Inglese et al. | | | |
| / | A72 | 6,340,742 | 1/22/02 | Burg et al. | | | |
| / | A73 | 6,348,192 | 2/19/02 | Chan et al. | | | |
| / | A74 | 6,444,792 | 9/3/02 | Gray et al. | | | |
| / | A75 | 6,475,717 | 11/5/02 | Ensle et al. | | | |
| / | A76 | 6,485,726 | 11/26/02 | Blumberg et al. | | | |
| / | A77 | 6,506,405 | 1/14/03 | Desai et al. | | | |
| / | A78 | 6,583,272 | 6/24/03 | Bailon | | | |
| / | A79 | 6,586,398 | 7/1/03 | Kinstler et al. | | | |
| RKH | A80 | 6,617,135 | 9/9/03 | Gillies et al. | | | |
| EXAMINER | Ramon K. Hummelt | | | DATE CONSIDERED | 9/7/04 | | |

FORM PTO - 1449

SECOND SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-003

APPLICANT(S): Gillies *et al.*

SERIAL NO.: 09/256,156

FILING DATE: February 24, 1999 GROUP: 1647

U.S. PATENT DOCUMENTS

| EXAM. INIT. | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE |
|----------------|-----|--------------------|----------|-----------------|-------|--------------|-------------------------------|
| RKH | A81 | 2001/0053539 | 12/20/01 | Lauffer et al. | | | |
| | A82 | 2002/0081664 | 6/27/02 | Lo et al. | | | |
| | A83 | 2002/0142374 | 10/3/02 | Gallo et al. | | | |
| | A84 | 2002/0147311 | 10/10/02 | Gillies et al. | | | |
| | A85 | 2002/0192222 | 12/19/02 | Blumberg et al. | | | |
| | A86 | 2002/0193570 | 12/19/02 | Gillies et al. | | | |
| | A87 | 2003/0003529 | 1/2/03 | Bayer | | | |
| | A88 | 2003/0044423 | 3/6/03 | Gillies et al. | | | |
| | A89 | 2003/0049227 | 3/13/03 | Gillies et al. | | | |
| | A90 | 2003/0105294 | 6/5/03 | Gillies et al. | | | |
| | A91 | 2003/0012789 | 1/6/03 | Blumberg et al. | | | |
| | A92 | 2003/0157054 | 8/21/03 | Gillies et al. | | | |
| | A93 | 2003/0166163 | 9/4/03 | Gillies | | | |
| RKH | A94 | 2003/0166877 | 9/4/03 | Gillies et al. | | | |

FOREIGN PATENT DOCUMENTS

| EXAM INIT. | | DOCUMENT NUMBER | DATE | COUNTRY CODE | CLASS | SUB CLASS | FILING DATE | ABSTRACT ONLY | ENGLISH LANG (Y/N) |
|---------------|-----|--------------------|----------|-----------------|-------|--------------|----------------|------------------|--------------------------|
| RKH | B83 | 0 318 554 B1 | 6/7/89 | EP | | | | | Y |
| | B84 | 0 640 619 A1 | 3/1/95 | EP | | | | | Y |
| | B85 | 0 668 353 A1 | 8/23/95 | EP | | | | | Y |
| | B86 | 1 088 888 A1 | 4/4/01 | EP | | | | | Y |
| | B87 | WO 94/24160 | 10/27/94 | PCT | | | | | Y |
| | B88 | WO 94/25055 | 11/10/94 | PCT | | | | | Y |
| | B89 | WO 99/60128 | 11/25/99 | PCT | | | | | Y |
| | B90 | WO 99/66054 | 12/23/99 | PCT | | | | | Y |
| RKH | B91 | WO 00/24893 | 5/4/00 | PCT | | | | | |

EXAMINER

David K. Himmelfarb

DATE CONSIDERED

9/7/04

FORM PTO - 1449

SECOND SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-003

APPLICANT(S): Gillies *et al.*

SERIAL NO.: 09/256,156

FILING DATE: February 24, 1999 GROUP: 1647


U.S. PATENT DOCUMENTS


| EXAM. INIT. | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE |
|----------------|------|--------------------|----------|------|-------|--------------|-------------------------------|
| RKH | B92 | WO 00/68376 | 11/16/00 | PCT | | | Y |
| | B93 | WO 00/78334 | 12/28/00 | PCT | | | Y |
| | B94 | WO 01/10912 | 2/15/01 | PCT | | | Y |
| | B95 | WO 01/36489 | 5/25/01 | PCT | | | Y |
| | B96 | WO 01/58957 | 8/16/01 | PCT | | | |
| | B97 | WO 02/02143 | 1/10/02 | PCT | | | |
| | B98 | WO 02/066514 | 8/29/02 | PCT | | | Y |
| | B99 | WO 02/072605 | 9/19/02 | PCT | | | |
| | B100 | WO 02/079232 | 10/10/02 | PCT | | | |
| | B101 | WO 02/079415 | 10/10/02 | PCT | | | |
| | B102 | WO 02/090566 | 11/14/02 | PCT | | | |
| | B103 | WO 03/015697 | 2/27/03 | PCT | | | Y |
| | B104 | WO 03/048334 | 6/12/03 | PCT | | | |
| RKH | B105 | WO 03/077834 | 9/25/03 | PCT | | | Y |

| EXAM. INIT. | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) | | | | | | |
|----------------|--|---|--|--|--|--|--|
| RKH | C143 | Afonso et al., (1994), "The Adjuvant Effect of Interleukin-12 in a Vaccine Against Leishmania Major," <u>Science</u> , 263:235-237. | | | | | |
| | C144 | Angal et al., (1993), "A Single Amino Acid Substitution Abolishes the Heterogeneity of Chimeric Mouse/Human (IgG4) Antibody," <u>Molecular Immunology</u> , 30(1):105-108. | | | | | |
| | C145 | Becker et al., (1996), "An Antibody-Interleukin 2 Fusion Protein Overcomes Tumor Heterogeneity by Induction of a Cellular Immune Response," <u>Proc. Natl. Acad. Sci.</u> , 93:7826-7831. | | | | | |
| | C146 | Becker et al., (1996), "Long-lived and Transferable Tumor Immunity in Mice after Targeted Interleukin-2 Therapy," <u>J Clin Invest.</u> , 98(12):2801-2804. | | | | | |
| | C147 | Becker et al., (1996), "T Cell-mediated Eradication of Murine Metastatic Melanoma Induced by Targeted Interleukin-2 Therapy," <u>J Exp. Med.</u> , 183(50):2361-6. | | | | | |
| RKH | C148 | Bissery et al., (1997), "The Taxoids," in <u>Cancer Therapeutics: Experimental and Clinical Agents</u> , Teicher, ed., 175-193. | | | | | |

| | | | |
|----------|-------------------------|-----------------|---------------|
| EXAMINER | <i>David R. Hummelt</i> | DATE CONSIDERED | <i>9/7/04</i> |
|----------|-------------------------|-----------------|---------------|

| FORM PTO - 1449 | | | | ATTORNEY DOCKET NO.: LEX-003 | | | |
|---|-----------------|------|---|--|-----------|----------------------------|--|
| SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT | | | | APPLICANT(S): Gillies <i>et al.</i> | | | |
| | | | | SERIAL NO.: 09/256,156 | | | |
| | | | | FILING DATE: February 24, 1999 GROUP: 1647 | | | |
| PATENT DOCUMENTS | | | | | | | |
| EXAM. INIT. | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE | |
| RKH | C149 | | Bitonti et al., (2002), "Transepithelial Absorption of an Erythropoietin-Fc Fusion Protein After Delivery to the Central Airways," <u>Respiratory Drug Delivery</u> , 8:309-312. | | | | |
| / | C150 | | Boissel et al., (1993), "Erythropoietin Structure-Function Relationships: Mutant Proteins that Test a Model of Tertiary Structure," <u>The Journal of Biological Chemistry</u> , 268(21):15983-15993. | | | | |
| / | C151 | | Briggs et al., (1974), "Hepatic Clearance of Intact and desialylated Erythropoietin," <u>American Journal of Physiology</u> , 227(6):1385-1388. | | | | |
| / | C152 | | Buchli et al., (1993), "Structural and Biologic Properties of a Human Aspartic Acid-126 Interleukin-2 Analog," <u>Archives of Biochemistry and Biophysics</u> , 307(2):411-415. | | | | |
| / | C153 | | Caton et al., (1986), "Structural and Functional Implications of a Restricted Antibody Response to a Defined Antigenic Region on the Influenza Virus Hemagglutinin," <u>The EMBO Journal</u> , 5(7):1577-1587. | | | | |
| / | C154 | | Chang et al., (1996), "A Point Mutation in Interleukin-2 that Alters Ligand Internalization," <u>Journal of Biological Chemistry</u> , 271(23):13349-13355. | | | | |
| / | C155 | | Chuang et al., (1993), "Effect of New Investigational Drug Taxol on Oncolytic Activity and Stimulation of Human Lymphocytes," <u>Gynecol. Oncol.</u> , 49:291-298. | | | | |
| / | C156 | | Chuang et al., (1994), "Alteration of Lymphocyte Microtubule Assembly, Cytotoxicity, and Activation by the Anticancer Drug Taxol," <u>Cancer Research</u> , 54:1286-1291. | | | | |
| / | C157 | | Collins et al., (1988), "Identification of Specific Residues of Human Interleukin 2 that Affect Binding to the 70-kDa Subunit (p70) of the Interleukin 2 Receptor," <u>Proc. Natl. Acad. Sci. USA</u> , 85:7709-7713. | | | | |
| / | C158 | | Cruse et al., (1995), <u>Illustrated Dictionary of Immunology</u> , CRC Press, NY, p.156-7. | | | | |
| / | C159 | | Darling et al., (2002), "Glycosylation of Erythropoietin Affects Receptor Binding Kinetics: Role of Electrostatic Interactions," <u>Biochemistry</u> , 41:14524-14531. | | | | |
| / | C160 | | Davis et al., (2003), "Immunocytokines: Amplification of Anti-cancer Immunity," <u>Cancer Immunol. Immunother.</u> , 52:297-308. | | | | |
| / | C161 | | Dolman et al., (1998), "Suppression of Human Prostate Carcinoma Metastases in Severe Combined Immunodeficient Mice by Interleukin 2 Immunocytokine Therapy," <u>Clin Cancer Res.</u> , 4(10):2551-7. | | | | |
| / | C162 | | Duncan et al., (1988), "The Binding Site for C1q on IgG," <u>Nature</u> , 332:738-740. | | | | |
| / | C163 | | Egrie et al., (2001), "Development and Characterization of Novel Erythropoiesis Stimulating Protein (NESP)," <u>Nephrol. Dial. Transplant.</u> , 16:3-13. | | | | |
| / | C164 | | Elliott et al., (1997), "Mapping of the Active Site of Recombinant Human Erythropoietin," <u>Blood</u> , 89(2):493-502. | | | | |
| RKH | C165 | | Fell et al., (1992), "Chimeric L6 Antitumor Antibody," <u>J. Biol. Chem.</u> , 267(122):15552-15558. | | | | |
| EXAMINER <i>Ronald K. Hummelt</i> | | | | DATE CONSIDERED <i>9/7/04</i> | | | |

| FORM PTO - 1449 | | | | ATTORNEY DOCKET NO.: LEX-003 | | | |
|---|---|--------------------|------|---|-------|--------------|-------------------------------|
| SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT | | | | APPLICANT(S): Gillies <i>et al.</i> | | | |
|  | | | | SERIAL NO.: 09/256,156 | | | |
| | | | | FILING DATE: February 24, 1999 GROUP: 1647 | | | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| EXAM. INIT. | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE |
| RKH | | C166 | | Fibi et al., (1995), "N- and O-Glycosylation Muteins of Recombinant Human Erythropoietin Secreted From BHK-21 Cells," <u>Blood</u> , 85(5):1229-1236. | | | |
| | / | C167 | | Frost et al., (1997), "A Phase I/IB Trial of Murine Monoclonal Anti GD2 Antibody 14.G2a Plus Interleukin-2 in Children with Refractory Neuroblastoma," <u>Cancer</u> , 80:317-33. | | | |
| | / | C168 | | Gan et al., (1999), "Specific enzyme-linked Immunosorbent Assays for Quantitation of Antibody-cytokine Fusion Proteins," <u>Clin. Diagn. Lab. Immunol.</u> , 6(2):236-42. | | | |
| | / | C169 | | Gillies et al., (1991), "Expression of Genetically Engineered Immunoconjugates of Lymphotoxin and a Chimeric Anti-ganglioside GD2 Antibody," <u>Hybridoma</u> , 10(3):347-56. | | | |
| | / | C170 | | Gillies et al., (2002), "Bi-functional Cytokine Fusion Proteins for Gene Therapy and Antibody-targeted Treatment of Cancer," <u>Cancer Immunol. Immunother.</u> , 51(8):449-60. | | | |
| | / | C171 | | Gillies et al., (2002), "Improved Circulating Half-life and eRfficacy of an Antibody-interleukin 2 Immunocytokine Based on Reduced Intracellular Proteolysis," <u>Clin. Cancer Res.</u> , 8(1):210-6. | | | |
| | / | C172 | | Greene et al., (1975), Neuronal Properties of Hybrid Neuroblastoma X Sympathetic Ganglion Cells," <u>Proc. Natl. Acad. Sci. USA</u> , 72(12):4923-4927. | | | |
| | / | C173 | | Griffon-Etienne et al., (1999), "Taxane-induced Apoptosis Decompresses Blood Vessels and Lowers Interstitial Fluid Pressure in Solid Tumors: Clinical Implications," <u>Cancer Research</u> , 59:3776-3782. | | | |
| | / | C174 | | Hammerling et al. (1996), "In Vitro Bioassay for Human Erythropoietin based on Proliferative Stimulation of an Erythroid Cell Line and Analysis of Carbohydrate-dependent Microheterogeneity," <u>Journal of Pharmaceutical and Biomedical Analysis</u> , 14:1455-1469. | | | |
| | / | C175 | | Hank et al., (1996), "Activation of Human Effector Cells by a Tumor Reactive Recombinant Anti-ganglioside GD2 Interleukin-2 Fusion Protein (ch14.18-IL2)," <u>Clin Cancer Res.</u> , 2(12):1951-9. | | | |
| | / | C176 | | Hank et al., (2003), "Determination of peak serum levels and immune response to the humanized anti-ganglioside antibody-interleukin-2 immunocytokine," <u>Methods Mol. Med.</u> , 85:123-31. | | | |
| | / | C177 | | Haraguchi, (1994), "Isolation of GD3 Synthase Gene by Expression Cloning of GM3 α -2,8-sialyltransferase cDNA using anti-GD2 Monoclonal Antibody," <u>Proc. Natl. Acad. Sci. USA</u> , 91(22):10455-9. | | | |
| | / | C178 | | Harris, (1995), "Processing of C-terminal lysine and arginine residues of proteins isolated from mammalian cell culture," <u>J. Chromatogr. A</u> , 705:129-134. | | | |
| | / | C179 | | Hezareh et al, (2001), "Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1," <u>J. Virol.</u> , 75(24):12161-8. | | | |
| | / | C180 | | Hornick et al, (1999), "Pretreatment with a monoclonal antibody/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors," <u>Clin. Cancer Res.</u> , 5:51-60. | | | |
| RKH | | C181 | | Hu et al., (1996), "A Chimeric Lym-I/Interleukin 2 Fusion Protein for Increasing Tumor Vascular Permeability and Enhancing Antibody Uptake," <u>Cancer Research</u> , 56:4998-5004. | | | |
| EXAMINER <i>Ramul K. Himmelfarb</i> | | | | DATE CONSIDERED <i>9/7/04</i> | | | |

| FORM PTO - 1449 | | | | ATTORNEY DOCKET NO.: LEX-003 | | | |
|---|---|--------------------|------|---|-------|--------------|-------------------------------|
| SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT | | | | APPLICANT(S): Gillies <i>et al.</i> | | | |
|  | | | | SERIAL NO.: 09/256,156 | | | |
| | | | | FILING DATE: February 24, 1999 GROUP: 1647 | | | |
| PATENT DOCUMENTS | | | | | | | |
| EXAM. INIT. | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE |
| RKH | / | C182 | | Idusogie et al., (2000), "Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc," <u>J. Immunol.</u> , 164(8):4178-4184. | | | |
| / | / | C183 | | Imboden et al., (2001), "The Level of MHC Class I Expression on Murine Adenocarcinoma Can Change the Antitumor Effector Mechanism of Immunocytokine Therapy," <u>Cancer Res.</u> , 61(4):1500-7. | | | |
| / | / | C184 | | Ju et al., (1987), "Structure-Function Analysis of Human Interleukin-2: Identification of Amino Acid Residues for Biological Activity," <u>Journal of Biological Chemistry</u> , 262(12):5723-5731. | | | |
| / | / | C185 | | Kato et al., (1997), "Mechanism for the Nonlinear Pharmacokinetics of Erythropoietin in Rats," <u>The Journal of Pharmacology and Experimental Therapeutics</u> , 283:520-527. | | | |
| / | / | C186 | | Kato et al., (1998), "Pharmacokinetics of Erythropoietin in Genetically Anemic Mice," <u>Drug Metabolism and Disposition</u> , 26:126-131. | | | |
| / | / | C187 | | Kitamura et al. (1989), "Establishment and Characterization of a Unique Human Cell Line that Proliferates Dependently on GM-CSF, IL-3, or Erythropoietin," <u>Journal of Cellular Physiology</u> , 140:323-334. | | | |
| / | / | C188 | | Kushner et al., (2001), "Phase II Trial of the Anti-GD2 Monoclonal-macrophage-colony-stimulating Factor for Neuroblastoma," <u>J. Clin. Oncol.</u> , 19:4189-94. | | | |
| / | / | C189 | | Locatelli et al., (2001), "Darbepoetin alfa Amgen," <u>Current Opinion in Investigational Drugs</u> , 2:1097-1104. | | | |
| / | / | C190 | | Lode et al., (1997), "Targeted interleukin-2 Therapy for Spontaneous Neuroblastoma Metastases to Bone Marrow," <u>J Natl Cancer Inst.</u> , 89(21):1586-94. | | | |
| / | / | C191 | | Lode et al., (1998), "Immunocytokines: A Promising Approach to Cancer Immunotherapy," <u>Pharmacol. Ther.</u> , 80(3):277-292. | | | |
| / | / | C192 | | Lode et al., (2000), "What to do with Targeted IL-2," <u>Drugs Today</u> , 36(5):321-36. | | | |
| / | / | C193 | | Lode et al., (2000), "Melanoma Immunotherapy by Targeted IL-2 Depends on CD4(+) T-cell Help Mediated by CD40/CD40L Interaction," <u>J. Clin. Invest.</u> , 105(11):1623-30. | | | |
| / | / | C194 | | Macdougall, (2002), "Optimizing the Use of Erythropoietic Agents—Pharmacokinetic and Pharmacodynamic Considerations," <u>Nephrol. Dial. Transplant.</u> , 17:66-70. | | | |
| / | / | C195 | | Metelitsa et al., (2002), "Antidisialoganglioside/granulocyte Macrophage-colony-stimulating Factor Fusion Protein Facilitates Neutrophil Antibody-dependent Cellular Cytotoxicity and Depends on FcγRII (CD32) and Mac-1 (CD11b/CD18) for Enhanced Effector Cell Adhesion and Azurophil Granule Exocytosis," <u>Blood</u> , 99(11):4166-73. | | | |
| / | / | C196 | | Mott et al., (1995), "The Solution Structure of the F42A Mutant of Human Interleukin 2," <u>J. Mol. Biol.</u> , 247:979-994. | | | |
| RKH | / | C197 | | Mueller et al. (1997), "Humanized Porcine VCAM-specific Monoclonal Antibodies with Chimeric IgG2/G4 Constant Regions Block Human Leukocyte Binding to Porcine Endothelial Cells," <u>Molecular Immunology</u> , 34(6):441-452. | | | |
| EXAMINER <i>Raul K. Hummel</i> | | | | DATE CONSIDERED <i>9/7/04</i> | | | |

FORM PTO - 1449


SECOND SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-003

APPLICANT(S): Gillies *et al.*

SERIAL NO.: 09/256,156


FILING DATE: February 24, 1999 GROUP: 1647



PATENT DOCUMENTS

| EXAM. INIT. | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE |
|---------------------------------|---|--------------------|------|---|-------|--------------|-------------------------------|
| RKH | / | C198 | | Mullins et al. (1997), "Taxol-mediated Changes in Fibrosarcoma-induced Immune Cell Function: Modulation of Antitumor Activities," <u>Cancer Immunol. Immunother.</u> , 45:20-28. | | | |
| | / | C199 | | Mullins et al., (1998), "Interleukin-12 Overcomes Paclitaxel-mediated Suppression of T-cell Proliferation," <u>Immunopharmacol. Immunotoxicol.</u> , 20(4):473-492. | | | |
| | / | C200 | | Naramura et al., "Mechanisms of Cellular Cytotoxicity Mediated by a Recombinant Antibody-IL2 Fusion Protein against Human Melanoma Cells," <u>Immunology Letters</u> , 39(1):91-9. | | | |
| | / | C201 | | Neal et al. (2003), "NXS2 Murine Neuroblastomas Express Increased Levels of MHC Class I Antigens upon Recurrence Following NK-dependent Immunotherapy," <u>Cancer Immunol Immunother.</u> , 53:41-52. | | | |
| | / | C202 | | Netti et al., (1995), "Time-dependent Behavior of Interstitial Fluid Pressure in Solid tumors: Implications for Drug Delivery," <u>Cancer Research</u> , 55:5451-5458. | | | |
| | / | C203 | | Netti et al., (1999), "Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules," <u>Proc. Nat. Acad. Sci. USA</u> , 96:3137-3142. | | | |
| | / | C204 | | Ngo et al., (1994), "The Protein Folding Problem and Tertiary Structure Prediction," pp. 433-440 and 492-495, Birkhauser Boston. | | | |
| | / | C205 | | Niethammer et al., (2002) "An oral DNA Vaccine against Human Carcinoembryonic Antigen (CEA) Prevents Growth and Dissemination of Lewis Lung Carcinoma in CEA Transgenic Mice," <u>Vaccine</u> , 20:421-9. | | | |
| | / | C206 | | Niethammer et al., (2001) "Targeted Interleukin 2 Therapy Enhances Protective Immunity Induced by an Autologous Murine Melanoma," <u>Cancer Res.</u> , 61(16):6178-84. | | | |
| | / | C207 | | Nimtze et al., (1993) Structures of Sialylated Oligosaccharides of Human Erythropoietin Expressed in Recombinant BHK-21 Cells," <u>Eur. J. Biochem.</u> , 213:39-56. | | | |
| | / | C208 | | Pancook et al., (1996), "Eradication of Established Hepatic Human Neuroblastoma Metastases in Mice with Severe Combined Immunodeficiency by Antibody-targeted Interleukin-2," <u>Cancer Immunol. Immunother.</u> , 42(2):88-92. | | | |
| | / | C209 | | Park et al., (2000), "Efficiency of Promoter and Cell line in High-level Expression of Erythropoietin," <u>Biotechnol. Appl. Biochem.</u> , 32:167-172. | | | |
| | / | C210 | | Polizzi et al., (1999), "A Novel Taxane with Improved Tolerability and Therapeutic Activity in a Panel of Human Tumor Xenografts," <u>Cancer Research</u> , 59:1036-1040. | | | |
| | / | C211 | | Reisfeld et al., (1996), "Antibody-interleukin 2 Fusion Proteins: A New Approach to Cancer Therapy," <u>J Clin Lab Anal.</u> , 10(3):160-6. | | | |
| RKH | / | C212 | | Reisfeld et al., (1996), "Involvement of B Lymphocytes in the Growth Inhibition of Human Pulmonary Melanoma Metastases in Athymic nu/nu Mice by an Antibody-lymphotoxin Fusion Protein," <u>Cancer Res.</u> , 56(8):1707-12. | | | |
| EXAMINER <i>David K. Hummer</i> | | | | DATE CONSIDERED <i>9/7/04</i> | | | |

FORM PTO - 1449

SECOND SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-003



APPLICANT(S): Gillies *et al.*

SERIAL NO.: 09/256,156

FILING DATE: February 24, 1999 GROUP: 1647

U.S. PATENT DOCUMENTS

| EXAM. INIT. | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE |
|-------------------------------------|---|--------------------|------|---|-------|--------------|-------------------------------|
| RKH | / | C213 | | Roessler et al., (1994), "Cooperative Interactions between the Interleukin 2 Receptor α and β Chains Alter the Interleukin 2-binding Affinity of the Receptor Subunits," <u>Proc. Natl. Acad. Sci. USA</u> , 91:3344-3347. | | | |
| / | / | C214 | | Ruehlmann et al., (2001), "MIG (CIXCL9) Chemokine Gene Therapy Combines with Antibody-cytokine Fusion Protein to Suppress Growth and Dissemination of Murine Colon Carcinoma," <u>Cancer Res.</u> , 61(23):8498-503. | | | |
| / | / | C215 | | Sabzevari et al., (1994), "A Recombinant Antibody-interleukin 2 Fusion Protein Suppresses Growth of Hepatic Human Severe Combined Immunodeficiency Mice," <u>Proc. Natl. Acad. Sci. USA</u> , 91(20):9626-30. | | | |
| / | / | C216 | | Sauve et al., (1991), "Localization in Human Interleukin 2 of the Binding Site of the α -chain (p55) of the Interleukin 2 Receptor," <u>Proc. Natl. Acad. Sci. USA</u> , 88:4636-4640. | | | |
| / | / | C217 | | Seidenfeld et al., (2001), "Epoietin Treatment of Anemia Associated with Cancer Therapy: A Systematic Review and Meta-analysis of controlled Clinical Trials," <u>Journal of National Cancer Institute</u> , 93:1204-1214. | | | |
| / | / | C218 | | Shanafelt et al., (2000), "A T-cell-Selective Interleukin 2 Mutein Exhibits Potent Antitumor Activity and is Well Tolerated <i>In Vivo</i> ," <u>Nature Biotechnology</u> , 18:1197-1202. | | | |
| / | / | C219 | | Sharma et al., (1999), "T cell-derived IL-10 Promotes Lung Cancer Growth by Suppressing both T cell and APC Function," <u>Journal of Immunology</u> , 163:5020-5028. | | | |
| / | / | C220 | | Shinkawa et al., (2003), "The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity," <u>J. Biol. Chem.</u> , 278:3466-3473. | | | |
| / | / | C221 | | Spiekermann et al., (2002), "Receptor-mediated Immunoglobulin G Transport Across Mucosal Barriers in Adult Life: Functional Expression of FcRn in the Mammalian Lung," <u>J. Exp. Med.</u> , 196:303-310. | | | |
| / | / | C222 | | Strom et al., (1996), "Therapeutic Approach to Organ Transplantation," <u>Therapeutic Immunology</u> , Blackwell Science, Chapter 36, pp. 451-456. | | | |
| / | / | C223 | | Sulitzeanu, (1993), "Immunosuppressive Factors in Human Cancer," pp. 247-267 in <u>Advances in Cancer Research</u> , Vol. 60, Vande Woude et al. (eds.), Academic Press, Inc. | | | |
| / | / | C224 | | Syed et al., (1998), "Efficiency of Signaling through Cytokine Receptors Depends Critically on Receptor Orientation," <u>Nature</u> , 395:511-516. | | | |
| / | / | C225 | | Thommesen et al., (2000), "Lysine 322 in the Human IgG3 CH2 Domain is Crucial for Antibody Dependent Complement Activation," <u>Mol. Immunol.</u> , 37(16):995-1004. | | | |
| / | / | C226 | | Villunger et al., (1997), "Constitutive Expression of Fas (Apo-1/CD95) Ligand on Multiple Myeloma Cells: A Potential Mechanism of Tumor-induced Suppression of Immune Surveillance," <u>Blood</u> , 90(1):12-20. | | | |
| / | / | C227 | | Watanabe et al., (1997), "Long-term Depletion of Naive T cells in Patients Treated for Hodgkin's Disease," <u>Blood</u> , 90(9):3662-3672. | | | |
| RKH | / | C228 | | Wells, (1990), "Additivity of Mutational Effect in Proteins," <u>Biochemistry</u> , 29(37):8509-8517. | | | |
| EXAMINER <i>David K. Himmelfarb</i> | | | | DATE CONSIDERED <i>9/7/04</i> | | | |

| FORM PTO - 1449 | | | | ATTORNEY DOCKET NO.: LEX-003 | | | | |
|--|-----------------|------|---|--|-----------------|----------------------------|--|---|
| SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT | | | | APPLICANT(S): Gillies <i>et al.</i> | | | | |
| | | | | SERIAL NO.: 09/256,156 | | | | |
| | | | | FILING DATE: February 24, 1999 GROUP: 1647 | | | | |
| U.S. PATENT DOCUMENTS | | | | | | | | |
| EXAM. INIT. | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE | | |
| RKH | C229 | | Wen et al., (1993), "Erythropoietin Structure-Function Relationships: High Degree of Sequence Homology Among Mammals," <u>Blood</u> , 82(5):1507-1516. | | | | | |
| | C230 | | Xiang et al., (1998), "Induction of Persistent Tumor-protective Immunity in Mice Cured of Established Colon Carcinoma Metastases," <u>Cancer Research</u> , 58(17):3918-3925. | | | | | |
| | C231 | | Xiang et al., (1999) "T Cell Memory against Colon Carcinoma is Long-lived in the Absence of Antigen," <u>J. Immunol.</u> , 163(7):3676-83. | | | | | |
| | C232 | | Xiang et al., (2001), "A Dual Function DNA Vaccine Encoding Carcinoembryonic Antigen and CD40 Ligand Trimer induces T Cell-mediated Protective Immunity Against Colon Cancer in Carcinoembryonic Antigen-Transgenic Mice," <u>J Immunol.</u> , 167(8):4560-5. | | | | | |
| | C233 | | Xiang et al., (2001), "Protective Immunity Against Human Carcinoembryonic Antigen (CEA) Induced by an Oral DNA Vaccine in CEA-transgenic Mice," <u>Clin Cancer Res.</u> , 7(3 Supp):S856-S864. | | | | | |
| | C234 | | Yu et al., (1998), "Phase I Trial of a Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 in Patients with Refractory Neuroblastoma and Osteosarcoma," <u>J. Clin. Oncol.</u> , 16(6):2169-80. | | | | | |
| RKH | C235 | | Zagozdzon et al. (1999), "Potentiation of Antitumor Effect of IL-12 in Combination with Paclitaxel in Murine Melanoma Model In Vivo," <u>International Journal of Molecular Medicine</u> , 4:645-648. | | | | | |
| EXAMINER | | |  | | DATE CONSIDERED | | |  |